MX2017013219A - Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. - Google Patents
Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos.Info
- Publication number
- MX2017013219A MX2017013219A MX2017013219A MX2017013219A MX2017013219A MX 2017013219 A MX2017013219 A MX 2017013219A MX 2017013219 A MX2017013219 A MX 2017013219A MX 2017013219 A MX2017013219 A MX 2017013219A MX 2017013219 A MX2017013219 A MX 2017013219A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- methods
- crystalline forms
- kinase inhibitor
- raf kinase
- Prior art date
Links
- 150000002688 maleic acid derivatives Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940102297 B-raf kinase inhibitor Drugs 0.000 title 1
- 239000002774 b raf kinase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- NGFFVZQXSRKHBM-FKBYEOEOSA-N 5-[[(1r,1as,6br)-1-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)CCC2=C1N=CC=C2OC(C=C1[C@@H]23)=CC=C1O[C@@H]3[C@H]2C1=NC2=CC=C(C(F)(F)F)C=C2N1 NGFFVZQXSRKHBM-FKBYEOEOSA-N 0.000 abstract 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a sales de maleato de 5-(((1R,1aS, 6bR)-1-(6-(trifluorometil)-1H-benzo[d]imidazol-2-il)-1a,6b-dihidr o-1H-ciclopropa[b]benzofuran-5-iI)oxi)-3,4-dihidro-1,8-naftiridin -2(1H)-ona (Compuesto 1), en particular la sal sesqui-maleato y sus formas cristalinas, métodos de preparación, composiciones farmacéuticas y usos terapéuticos para el tratamiento de enfermedades o trastornos mediados por BRAF u otras quinasas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015076639 | 2015-04-15 | ||
PCT/CN2016/079251 WO2016165626A1 (en) | 2015-04-15 | 2016-04-14 | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017013219A true MX2017013219A (es) | 2018-02-15 |
Family
ID=57125563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013219A MX2017013219A (es) | 2015-04-15 | 2016-04-14 | Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US10351559B2 (es) |
EP (2) | EP3283486B1 (es) |
JP (3) | JP7320741B2 (es) |
KR (2) | KR102643609B1 (es) |
CN (2) | CN113307805A (es) |
AU (1) | AU2016248376B2 (es) |
CA (1) | CA2981746C (es) |
EA (1) | EA035680B1 (es) |
IL (2) | IL255555B (es) |
MX (1) | MX2017013219A (es) |
NZ (1) | NZ735715A (es) |
SG (1) | SG11201707984TA (es) |
TW (3) | TWI736531B (es) |
WO (1) | WO2016165626A1 (es) |
ZA (1) | ZA201706392B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
MX352617B (es) | 2011-12-31 | 2017-12-01 | Beigene Ltd | Compuestos triciclicos fusionados como inhibidores de cinasa raf. |
CN105120866B (zh) | 2013-01-23 | 2020-02-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
TWI736531B (zh) | 2015-04-15 | 2021-08-21 | 英屬開曼群島商百濟神州有限公司 | B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途 |
JP6993056B2 (ja) | 2016-07-05 | 2022-02-15 | ベイジーン リミテッド | 癌治療のためのpd-1アンタゴニスト及びraf阻害剤の組合せ |
KR20240032157A (ko) | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
JP2021533154A (ja) * | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス, インコーポレイテッド | 多形化合物およびその使用 |
LT3873894T (lt) * | 2018-10-31 | 2023-06-26 | Les Laboratoires Servier | Naujoji bcl-2 inhibitoriaus druska, susijusi kristalinė forma, jos gamybos būdas ir farmacinės kompozicijos, kurių sudėtyje ji yra |
CN111484489B (zh) * | 2019-01-25 | 2023-05-23 | 百济神州(北京)生物科技有限公司 | 无定形的b-raf激酶二聚体抑制剂 |
CN111484488A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州(北京)生物科技有限公司 | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a |
US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス, インコーポレイテッド | 多形化合物およびその使用 |
CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
WO2023240178A1 (en) * | 2022-06-08 | 2023-12-14 | Mapkure, Llc | Methods of treating cancer with a b-raf inhibitor |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1828186A1 (en) | 2004-12-13 | 2007-09-05 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
WO2007067444A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
US7442808B2 (en) | 2006-05-15 | 2008-10-28 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
ES2373587T3 (es) | 2006-08-23 | 2012-02-06 | Pfizer Products Inc. | Compuestos de pirimidona como inhibidores de gsk-3. |
WO2008030448A1 (en) | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
KR20090130345A (ko) | 2007-05-04 | 2009-12-22 | 아이알엠 엘엘씨 | C-kit 및 pdgfr 키나제 억제제로서의 화합물 및 조성물 |
US20100197924A1 (en) * | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
WO2012121764A1 (en) * | 2010-11-25 | 2012-09-13 | Ratiopharm Gmbh | Novel salts and polymorphic forms of afatinib |
MX352617B (es) * | 2011-12-31 | 2017-12-01 | Beigene Ltd | Compuestos triciclicos fusionados como inhibidores de cinasa raf. |
TWI736531B (zh) | 2015-04-15 | 2021-08-21 | 英屬開曼群島商百濟神州有限公司 | B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途 |
-
2016
- 2016-04-14 TW TW105111715A patent/TWI736531B/zh active
- 2016-04-14 CN CN202110419671.1A patent/CN113307805A/zh active Pending
- 2016-04-14 US US15/565,807 patent/US10351559B2/en active Active
- 2016-04-14 KR KR1020177033101A patent/KR102643609B1/ko active IP Right Grant
- 2016-04-14 MX MX2017013219A patent/MX2017013219A/es unknown
- 2016-04-14 NZ NZ735715A patent/NZ735715A/en unknown
- 2016-04-14 WO PCT/CN2016/079251 patent/WO2016165626A1/en active Application Filing
- 2016-04-14 KR KR1020247006890A patent/KR20240049684A/ko active Search and Examination
- 2016-04-14 EA EA201792254A patent/EA035680B1/ru unknown
- 2016-04-14 SG SG11201707984TA patent/SG11201707984TA/en unknown
- 2016-04-14 TW TW112101259A patent/TWI832668B/zh active
- 2016-04-14 JP JP2017553956A patent/JP7320741B2/ja active Active
- 2016-04-14 AU AU2016248376A patent/AU2016248376B2/en active Active
- 2016-04-14 TW TW110125410A patent/TWI792406B/zh active
- 2016-04-14 EP EP16779601.0A patent/EP3283486B1/en active Active
- 2016-04-14 CA CA2981746A patent/CA2981746C/en active Active
- 2016-04-14 CN CN201680021109.0A patent/CN107531682B/zh active Active
- 2016-04-14 EP EP22179294.8A patent/EP4119559A1/en active Pending
-
2017
- 2017-09-21 ZA ZA2017/06392A patent/ZA201706392B/en unknown
- 2017-11-09 IL IL255555A patent/IL255555B/en unknown
-
2021
- 2021-01-22 JP JP2021009106A patent/JP7383652B2/ja active Active
- 2021-10-31 IL IL287740A patent/IL287740A/en unknown
-
2023
- 2023-11-08 JP JP2023190552A patent/JP2024012540A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017013219A (es) | Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
PH12017500166A1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MX2016009403A (es) | Compuestos heterociclicos. | |
MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
SA518400333B1 (ar) | شكل متعدد الأشكال من n- {6-(2-هيدروكسي بروبان-2-يل) -2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد | |
WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
MX2017013886A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa. | |
NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
PH12016502432A1 (en) | 1h-1,8-naphthyridin-2-ones as anti proliferative compounds | |
MX2018004256A (es) | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. | |
NZ712369A (en) | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists | |
EA202190043A2 (ru) | Замещенные гетероциклические производные как ингибиторы циклин-зависимой киназы (cdk) |